Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4545491 | 1.00 | ADRB2 (0.38) | ADRB2ADRB1CYP2D6NR3C1ADRA1A | |
| SCHEMBL22045344 | 0.79 | ADRB2 (0.38) | ADRB2ADRB1CYP2D6NR3C1ADRA1A | |
| SCHEMBL14755169 | 0.78 | POLB (0.35) | TDP1 | |
| SCHEMBL9407492 | 0.76 | ADRB2 (0.36) | ADRB2ADRB1CYP2D6ADRA1AADRB3 | |
| SCHEMBL178393 | 0.76 | — | — | |
| SCHEMBL13030869 | 0.75 | NR2E1 (0.46) | ADRB2ADRB1CYP2D6NR3C1ADRA1A | |
| SCHEMBL4845727 | 0.75 | ADRB2 (0.54) | ADRB2ADRB1CYP2D6NR3C1ADRA1A | |
| SCHEMBL27579670 | 0.75 | ADRB2 (0.36) | ADRB2ADRB1CYP2D6NR3C1ADRA1A | |
| SCHEMBL19883607 | 0.75 | — | — | |
| SCHEMBL19996351 | 0.73 | MAPK1 (0.44) | ADRB2ADRB1CYP2D6ADRB3PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | ADRB2 223/4885ADRB1 170/4885CYP2D6 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.